Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of “patented” ATO is prohibitive because of patent rights. “Generic” ATO has been used in a few countries, but its implic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: Bankar, Aniket, Korula, Anu, Kulkarni, Uday P., Devasia, Anup J., Fouzia, NA, Lionel, Sharon, Abraham, Aby, Balasubramanian, Poonkuzhali, Janet, Nancy Beryl, Nair, Sukesh C., Sezlian, S, Jeyaseelan, Visali, Jeyaseelan, N, Prasad, Jasmine, George, Biju, Mathews, Vikram
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7617145/
https://ncbi.nlm.nih.gov/pubmed/31863602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16343
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki